ZIOPHARM ONCOLOGY INC | Business Operations | Business Contracts

Fourth Amendment to the Cooperative Research and Development Agreement, dated June 24, 2022, by and between the National Cancer Institute and the Registrant (Filed With SEC on August 15, 2022)

Agreement, by and among ZIOPHARM Oncology, Inc., WaterMill Asset Management Corp. Robert W. Postma, Jamie Vieser, and Holger Weis, dated February 4, 2021 (Filed With SEC on February 5, 2021)

Placement Agency Agreement, dated July 26, 2019, by and among Ziopharm Oncology, Inc. and Raymond James & Associates, Inc (Filed With SEC on August 1, 2019)

Third Amendment to the Cooperative Research and Development Agreement, dated March 15, 2022, by and among the National Cancer Institute and the Registrant (Filed With SEC on March 30, 2022)

Fifth Amendment to Research and Development Agreement, dated October 22, 2019 by and among the Registrant and The University of Texas MD Anderson Cancer Center (Filed With SEC on March 2, 2020)

2019 Research and Development Agreement, dated October 22, 2019, by and between the Registrant and The University of Texas MD Anderson Cancer Center (Filed With SEC on March 2, 2020)

Fourth Amendment to Research and Development Agreement, dated September 19, 2019 by and between the Registrant, The University of Texas MD Anderson Cancer Center and Precigen, Inc (Filed With SEC on November 7, 2019)

Cooperative Research and Development Agreement, dated January 9, 2017, by and among the National Cancer Institute, Ziopharm Oncology, Inc. and Intrexon Corporation (Filed With SEC on September 26, 2019)

Amendment #1 to the Cooperative Research and Development Agreement, dated March 23, 2018, by and among the National Cancer Institute, Ziopharm Oncology, Inc., Intrexon Corporation... (Filed With SEC on September 26, 2019)

Amendment #2 to the Cooperative Research and Development Agreement, dated February 1, 2019, by and among the National Cancer Institute, Ziopharm Oncology, Inc. and Precigen, Inc (Filed With SEC on September 26, 2019)

Amendment #1 to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of August... (Filed With SEC on March 5, 2019)

Amendment #2 to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of... (Filed With SEC on March 5, 2019)

Amendment #3 to the Research and Development Agreement by and among the Registrant, Intrexon Corporation and The University of Texas M.D. Anderson Cancer Center dated as of... (Filed With SEC on March 5, 2019)

ZIOPHARM ONCOLOGY INC (65) | Business Operations (13)